1,414 results on '"Faivre-Finn, C"'
Search Results
2. Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK
3. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial
4. A novel use for routine CBCT imaging during radiotherapy to detect COVID-19
5. Evaluation of Prognostic and Predictive Models in the Oncology Clinic
6. Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK
7. 77P Experience pooling control arms within a complex phase I drug-radiotherapy (RT) platform trial
8. The Impact of Intra-thoracic Anatomical Changes upon the Delivery of Lung Stereotactic Ablative Radiotherapy
9. Neutrophil–Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer
10. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
11. Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
12. Predicting the Risk of Disease Recurrence and Death Following Curative-intent Radiotherapy for Non-small Cell Lung Cancer: The Development and Validation of Two Scoring Systems From a Large Multicentre UK Cohort
13. Introducing magnetic resonance imaging into the lung cancer radiotherapy workflow – An assessment of patient experience
14. Palliative Lung Radiotherapy: Higher Dose Leads to Improved Survival?
15. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
16. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
17. OA06.03 An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer
18. EP08.01-03 Lymphocyte Count Pre-immunotherapy Predicts Progression-Free Survival in Stage III NSCLC Treated with Chemoradiotherapy and Immunotherapy
19. P1.28-09 Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel
20. P1.28-08 Definition of Resectable Stage III Non-Small Cell Lung Cancer: A Systematic Review from EORTC Lung Cancer Group
21. P2.01-04 An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC
22. Evaluation of Observer Variation as Natural Experiment to Detect Sensitive Heart Subregions
23. Cancers bronchiques de stade III: rôle de l’onco-radiothérapeute
24. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial
25. Prise en charge des formes oligométastatiques : l’avis de l’oncologue thoracique
26. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
27. Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms
28. Benefit of using motion compensated reconstructions for reducing inter-observer and intra-observer contouring variation for organs at risk in lung cancer patients
29. PO-1310 Predictors of outcomes in patients with NSCLC treated with chemoradiotherapy & immunotherapy.
30. MO-0467 Impact of the COVID-19 pandemic on patient outcomes after curative-intent radiotherapy in the UK
31. PO-2117 CTV-free lung planning: Can we reduce toxicity whilst maintaining local control?
32. PO-1676 Optimising heart substructure visibility in 4D planning CT by compensating respiratory motion
33. PD-0901 Methodology to monitor changes in ECG in patients with lung cancer after radiotherapy
34. OC-0608 Do patients with lung cancer and a genetic risk for rheumatoid arthritis have increased toxicity?
35. PO-1653 Auto-contouring of cardiac avoidance region for cardiac sparing lung radiotherapy
36. OC-0611 Lungtech EORTC 22113-08113 prospective multicenter trial: SBRT for central lung tumors.
37. MO-0474 Is comorbidity associated with interruption of RT treatment in patients with lung cancer?
38. 174TiP PRIMALung (EORTC-1901): Prophylactic cerebral irradiation or active brain magnetic resonance imaging surveillance in small cell lung cancer patients
39. Immune Checkpoint Inhibitors in Lung Cancer – An Unheralded Opportunity?
40. Cancers bronchiques de stade III : rôle de l’onco-radiothérapeute: Stage III Non-Small Cell Lung cancer: role of the radiation oncologist
41. Prise en charge des cancers bronchiques non à petites cellules oligométastatiques: Management of non-small oligometastatic lung cancer: Update 2021
42. The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer
43. The Current Role of Radiotherapy in the Treatment of Small Cell Lung Cancer
44. 28MO Adapting the Time-to-Event Continual Reassessment Method (TiTE-CRM) to include consolidation immunotherapy in a phase I drug-radiotherapy platform trial
45. Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study
46. Whole Tumor vs. FDG-Directed Dose Escalation in Patients with Locally Advanced NSCLC: Evaluation of Isotoxic Treatment Plans from the Randomized ARTFORCE PET-Boost Trial
47. Final Results of an International Delphi Consensus Study Regarding the Optimal Management of Radiation Pneumonitis
48. Retrospective Fat Suppression for Lung Radiotherapy Planning with CycleGANs
49. EP05.01-007 CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC)
50. EP08.03-005 HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.